BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlaxoSmithKline (GSK) And Bentley Pharmaceuticals (BNT) Mutually Agree To Dismiss All Claims Of Paroxetine Patent Infringement In Spain


10/19/2005 5:10:20 PM

EXETER, N.H.--(BUSINESS WIRE)--May 11, 2005--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe, today announced that a Spanish court terminated judicial proceedings among Bentley's Spanish subsidiary, Laboratorios Belmac S.A. and its subsidiaries, and SmithKline Beecham PLC, SmithKline Beecham, S.A. and GlaxoSmithKline S.A. (collectively "Glaxo"), upon agreement among the parties to dismiss, without recourse, all paroxetine-related patent infringement claims in their litigation in Spain. This settlement arises out of a suit brought by Glaxo against Bentley in October 2003 alleging that Bentley had violated Glaxo's patents in the production of paroxetine products after Bentley launched its paroxetine product line in May 2003. The complaint, which was brought in Madrid against Bentley's Spanish subsidiaries, followed a preliminary injunction that Glaxo sought against Bentley in 2003 that was dismissed in June 2003. This 2005 agreement also dismissed Bentley's counterclaim requesting that the court declare Glaxo's asserted patent invalid.

Read at AP
Read at BioSpace.com

AP
BioSpace.com
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES